clinical trial · NCT07194070
A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry
Janssen Research & Development, LLC·—·recruiting·n = 175
Hemolytic Disease of the Fetus and NewbornStandard of Care
brief summary
The purpose of this non-interventional study is to prospectively evaluate the risk of anemia (decreased red blood cells) in fetuses (baby before birth) and neonates (baby just after birth) of pregnant participants who are at risk for hemolytic disease of the fetus and newborn (HDFN) and receiving standard of care (SoC). HDFN is a blood disease that occurs in babies before birth or just after birth when the blood types of the pregnant individual and babies are incompatible, thus resulting in fast breakdown of red blood cells (RBCs) of the fetus/baby.
started
Dec 17, 2025
primary completion
May 26, 2030
completion
Sep 30, 2030
last updated
Apr 13, 2026
official title
Global Prospective Hemolytic Disease of the Fetus and Newborn Registry
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol